Fiasp - Australia

[Amity Island]

Fiasp, which is manufactured by pharmaceutical giant Novo Nordisk, is scheduled to come off the pharmaceutical benefits scheme (PBS) from 1 April, sending the price from $30 to $230 a month.

My fast-acting insulin is being taken off the PBS – could my glucose monitor be next? | Nicholas Edwards

Without a government subsidy the price of Fiasp will soar. That will hurt a lot of Australians with diabetes

www.theguardian.com

 

[everydayupsanddowns]

Wow! I had no idea that happened outside of the US

 

[Eddy Edson]

It's a decision by Novo, which says the govt subsidy it gets for Fiasp under the PBS is too low - it says lower than some older/slower insulins.

It smells like a bureaucratic screw-up to me & my guess is there will be a fix. Fingers crossed.